Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE

Total Page:16

File Type:pdf, Size:1020Kb

Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE Send Orders for Reprints to [email protected] 3385 Cur rent Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-5294 Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Impact Factor: 2.9 The international Present and Future journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Peng Li*, Gretchen L. Snyder and Kimberly E. Vanover Intra-Cellular Therapies Inc, 430 East 29th Street, Suite 900, New York, NY 10016, USA Abstract: Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approxi- mately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demon- strate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are A R T I C L E H I S T O R Y largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social Received: April 07, 2016 Revised: May 20, 2016 function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter Accepted: May 23, 2016 systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway DOI: 10.2174/1568026616666160608 are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the un- 084834 intentional engagement of multiple pharmacological targets or even the excessive engagement of in- tended pharmacological targets can lead to undesired consequences and poor tolerability. In this arti- cle, we will review marketed typical and atypical antipsychotics and new therapeutic agents targeting dopamine receptors and other neurotransmitters for the treatment of schizophrenia. Representative typical and atypical antipsychotic drugs and new investigational drug candidates will be systemati- cally reviewed and compared by reviewing structure-activity relationships, pharmacokinetic proper- ties, drug metabolism and safety, pharmacological properties, preclinical data in animal models, clinical outcomes and associated side effects. Keywords: Antipsychotic, Aripiprazole, Clozapine, Dopamine, Haloperidol, ITI-007, Risperidone, Schizophrenia. 1. INTRODUCTION tributes to the pathophysiology of this disorder [7-9]. Subse- quent research suggests that the serotonergic pathway also 1.1. Schizophrenia plays an important role [10]. Recent molecular genetic stud- Schizophrenia is a chronic neuropsychiatric illness af- ies conducted by an international schizophrenia consortium fecting approximately 1% of the global population [1, 2]. strongly support the fact that schizophrenia is a polygenic Individuals with the disorder may experience hallucinations, disease [11]. delusions, suspiciousness, and conceptual disorganization among other so called positive symptoms. These positive 1.2. Current Treatments for Schizophrenia symptoms can be accompanied by social withdrawal, blunted It is well accepted that the positive symptoms of schizo- affect, emotional withdrawal and asociality, collectively re- ferred as negative symptoms. Cognitive impairment is also a phrenia are associated with hyperdopaminergic neurotrans- mission in the brain, particularly in the mesolimbic dopa- core feature of schizophrenia [3]. Together with other resid- mine pathway, while the negative symptoms and cognitive ual symptoms including depression, the broad array of symp- deficits associated with schizophrenia may be caused by hy- toms associated with schizophrenia results in significant im- podopaminergic activity in the mesocortical pathway [12- pairment of social function with the inability to fully inte- 16]. Dopamine D receptor antagonists, such as chlorpro- grate into one’s family and into the workplace. Although the 2 etiology and pathology of schizophrenia remain largely un- mazine and haloperidol, have demonstrated clinical efficacy in the reduction of positive symptoms. However, these first resolved [4-6], dopamine system dysfunction clearly con- generation antipsychotics are ineffective and may exacerbate negative symptoms and cognitive deficits associated with *Address correspondence to this author at Intra-Cellular Therapies Inc, 430 schizophrenia. As detailed below, they bind to a number of East 29th Street, Suite 900, New York, NY 10016, United States; receptor systems, many of which contribute to serious side Tel: +1-(646)-440-9388; Fax: +1-(646)-440-9334; effects. Although modulating dopamine neurotransmission E-mail: [email protected] 1873-5294/16 $58.00+.00 © 2016 Bentham Science Publishers Current Topics in Medicinal Chemistry 3386 Current Topics in Medicinal Chemistry, 2016, Vol. 16, No. 29 Li et al. has been a dominant therapeutic approach, findings from the third generation antipsychotics. Presynaptic partial ago- both clinical and preclinical research have suggested that nism at D2 receptors has allowed for a further reduction in dysregulation of other neurotransmitter systems including EPS and hyperprolactinemia, but postsynaptic partial ago- serotonin, glutamate, gamma-aminobutyric acid (GABA) nism at D2 receptors has been associated with relatively high and acetylcholine also contribute to the pathophysiology of levels of akathisia and more recently with uncontrollable schizophrenia [17]. The dysfunction of multiple neurotrans- pathological urges to gamble, binge eat, shop and have sex mitter systems in schizophrenia indicated that drugs selec- [22]. Currently, new investigational drugs with novel tively targeting one neurotransmission pathway are unlikely mechanisms are being developed in order to identify better to meet the therapeutic needs of this heterogeneous disorder. therapeutic agents that can treat not only the positive symp- Treatment involving the modulation of multiple targets may toms of schizophrenia but also enhance social function and be more effective to address social dysfunction as well as improve safety and tolerability. For instance, ITI-007 (7) positive symptoms associated with schizophrenia. In this represents a first-in-class small molecule therapeutic agent article, we will review marketed typical and atypical antipsy- interacting with serotonergic, dopaminergic and glutamater- chotics as well as novel therapeutic agents targeting dopa- gic neurotransmitter targets in a complex, unique and re- mine D2 receptors and other neurotransmitters systems for gionally selective manner [23, 24]. We will briefly review the treatment of schizophrenia. The structure-activity rela- the first and second generation antipsychotics since these tionships (SAR) and receptor binding profiles of these com- antipsychotics have been reviewed extensively [25-27]. pounds will be discussed. Representative compounds from Newer antipsychotic drug candidates targeting dopamine each generation of antipsychotics will be compared in vari- along with other neurotransmitter systems will be discussed ous aspects including pharmacological profiles, efficacy in in detail. Representative antipsychotic drugs, haloperidol (2), behavioral models, clinical outcomes and associated side clozapine (3), risperidone (4), aripiprazole (5), and ITI-007 effects. (7), representing a new investigational drug for schizophre- nia, will be systematically reviewed. 2. DEVELOPMENT OF ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA 2.1. Haloperidol and Other First-Generation Antipsy- chotics (FGA) Since the first antipsychotic, chlorpromazine (1), was in- troduced in the 1950s [18], many other antipsychotic drugs Typical antipsychotics exert their action predominantly have been discovered and marketed during the past six dec- through dopamine D2 receptor antagonism. As exemplified ades. While the chemical structures of these antipsychotics in (Fig. 1), these first generation antipsychotics may be gen- are quite diverse, they all have somewhat similar pharmacol- erally categorized into several chemical classes, including (a) ogical action, mainly dopamine D2 receptor blockade. These phenothiazines, such as chlorpromazine (1) [28, 29], per- compounds generally can be classified as “typical” and phenazine (8) [30, 31], fluphenazine (9) [32, 33], trifluop- “atypical” antipsychotics based upon both pattern of clinical erazine (10) [34, 35] and levomepromazine (11) [36], (b) effects and mechanism of action [19, 20]. The typical antip- thioxanthenes, such as chlorprothixene (12) [37, 38], clopen- sychotic drugs, represented by haloperidol (2) and chlorpro- thixol (13) [39] and thiothixene (14) [40], and (c) diphenyl- mazine (1), are also called the first generation antipsychotics butylpiperidines, such as pimozide (15) [41, 42], fluspirilene (FGA) or neuroleptics. The FGAs are effective at reducing (16) [43] and penfluridol (17) [44]. positive symptoms associated with schizophrenia, but are Butyrophenones are another important class of com- largely limited by extrapyramidal motor side effects (EPS), pounds with antipsychotic activities. Haloperidol (2) is a hyperprolactinemia and cognitive dulling. These adverse well-known typical antipsychotic drug that belongs to this effects are likely mediated by high dopamine D receptor 2 chemical class [45, 46]. Other drugs, such as bromperidol occupancy. The serendipitous discovery of compounds
Recommended publications
  • (Schizophrenia) – Forecast and Market Analysis to 2022
    REFERENCE CODE GDHC367DFR | PUBLICATION DATE FEBRUARY 2014 BREXPIPRAZOLE (SCHIZOPHRENIA) – FORECAST AND MARKET ANALYSIS TO 2022 BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Table below provides a summary of the key May have an effect on negative symptoms. metrics for Brexpiprazole in the seven major Otsuka has a strong presence in the pharmaceutical markets during the forecast period schizophrenia drug market. upto 2022. Conversely, the major barriers for the growth of Brexpiprazole : Key Metrics in the Seven Major Brexpiprazole in the schizophrenia market include: Pharmaceutical Markets, 2012–2022 Key Events (2012-2022) Level of Impact Higher cost of therapy compared to older Anticipated launch of Brexpiprazole in ↑↑↑ medications. US(2015) Anticipated launch of Brexpiprazole in ↑↑ Requires daily oral dosing. Japan (2016) 2022 Market Sales The figure below illustrates Brexpiprazole sales in US $1,648.9m the 7MM by region during the forecast period. 5EU $28.4m Japan $105.8m Sales for Brexpiprazole by Region, 2022 7MM $1,783.1m 5.9% 1.6% 2022 Source: GlobalData. Total : $1,783.1m 7MM = US, France, Germany, Italy, Spain, UK, Japan; 5EU = France, Germany, Italy, Spain, UK US Sales of Brexpiprazole in Global Schizophrenia 5EU Market, 2022 Japan Brexpiprazole sales are expected to increase from $176.2 million upon launch in 2015 to $1,783.1 92.5% million in 2022. Source: GlobalData. Major growth drivers for Brexpiprazole in the Schizophrenia market over the forecast period include: Structurally similar to Otsuka’s Abilify, the current market leader in the schizophrenia drug market. Improved tolerability and similar efficacy to Abilify demonstrated in clinical trials.
    [Show full text]
  • Bifeprunox: a Novel Antipsychotic Agent with Partial Agonist Properties at Dopamine D2 and Serotonin 5-HT1A Receptors
    DRUG EVALUATION Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors Marie-Louise G Most second-generation, atypical, dopamine (DA) D2/5-HT2 blocking antipsychotics still Wadenberg induce extrapyramidal side effects (EPS) in higher doses. Weight gain and metabolic University of Kalmar, disturbances are also a problem, and negative and cognitive symptoms have not been Department of Natural Sciences, Norra Vagen 49, sufficiently addressed. The current brain DA mesolimbic hyperactive/mesocortical SE-391 82 Kalmar, Sweden hypoactive hypothesis of schizophrenia suggests that DA D2/5-HT1A receptor partial agonist Tel.: +46 480 446 277; properties may be more efficacious with less side effects. DA D2 receptor partial agonists Fax: +46 480 446 244; may stabilize a hyperactive/hypoactive DA condition. Additional 5-HT stimulation may marie-louise.wadenberg@ 1A hik.se enhance therapeutic efficacy and also improve EPS liability profile. In clinical trials in schizophrenic patients, the novel DA D2/5-HT1A partial agonist bifeprunox indeed demonstrates therapeutic efficacy, a safe EPS profile and appears beneficial regarding weight gain, prolactin, blood lipid and glucose levels and cardiac rhythm. The data on bifeprunox are promising and suggest that combined DA D2/5-HT1A partial agonism may well be important properties for future-generation antipsychotics. Bifeprunox, a novel antipsychotic agent with a (DA D1, D2, D4, 5-HT2A/C, 5-HT1A, hista- so-called third-generation atypical pharmacolog- mine H1, α1, α2, cholinergic muscarinic recep- ical profile, is currently in clinical trials and tor affinity) and comparatively lower affinity for expected to launch as a schizophrenia therapy in the DA D2 receptor than traditional APDs.
    [Show full text]
  • HTR1A Polymorphisms and Clinical Efficacy Of
    International Journal of Neuropsychopharmacology, (2016) 19(5): 1–10 doi:10.1093/ijnp/pyv125 Advance Access publication November 14, 2015 Research Article research article HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis Yoshiteru Takekita, MD, PhD; Chiara Fabbri, MD; Masaki Kato, MD, PhD; Yosuke Koshikawa, MA; Aran Tajika, MD; Toshihiko Kinoshita, MD, PhD; Alessandro Serretti, MD, PhD Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy (Drs Takekita, Fabbri, and Serretti); Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan (Drs Takekita, Kato, Koshikawa, and Kinoshita); Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan (Dr Tajika). Correspondence: Yoshiteru Takekita, MD, PhD, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Viale Carlo Pepoli 5, Bologna, 40123, Italy ([email protected]). Abstract Background: This meta-analysis was conducted to evaluate whether HTR1A gene polymorphisms impact the efficacy of antipsychotic drugs in patients with schizophrenia. Methods: Candidate gene studies that were published in English up to August 6, 2015 were identified by a literature search of PubMed, Web of Science, and Google scholar. Data were pooled from individual clinical trials considering overall symptoms, positive symptoms and negative symptoms, and standard mean differences were calculated by applying a random-effects model. Results: The present meta-analysis included a total of 1281 patients from 10 studies. Three polymorphisms of HTR1A (rs6295, rs878567, and rs1423691) were selected for the analysis. In the pooled data from all studies, none of these HTR1A polymorphisms correlated significantly with either overall symptoms or positive symptoms.
    [Show full text]
  • FDA Provides New Guidance on Antipsychotic Usage During
    Clinical News Peter F. Buckley, MD Editor-in-Chief FDA Provides New Guidance on impact of prolonged exposure to antipsychotic medications Antipsychotic Usage during upon total brain volume, as well as both gray matter and Pregnancy caudate-putamen volumes. Modest volumetric reductions were observed. There appeared to be a dose effect of antipsy- The U.S. Food and Drug Administration (FDA), tak- chotics as well. Although the effects were not independent ing stock of all available and new pharmacoepidemiological of other factors that are known to influence potential brain information on antipsychotic medication use, has provided changes—namely, duration of follow-up, illness severity, and updated guidance on prescribing antipsychotics during and comorbid substance abuse—the effect of medications per- immediately after pregnancy. Firstly, the FDA report affirms sisted even when these other influences were taken into ac- the long-held clinical message that untreated psychosis in count statistically. This is a noteworthy observation. the expectant mother is associated with (far) greater risk While the results are still open to other interpretations, than the risks associated with continued use of antipsychot- the observations for this study are sobering. They are also ics. Nevertheless, the report cautions about risks of antipsy- in line with earlier preclinical studies from the University chotic medications for extrapyramidal side effects (EPS) and of Pittsburgh that have demonstrated potential neurotoxic withdrawal side effects in the newborn. The report cites out- effects of antipsychotic medication upon selective neurons. comes for 69 instances of EPS and withdrawal side effects Nevertheless, the “jury is still out” on this contentious top- that were reported to the FDA up until the fall of 2008.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Revision of Precautions Asenapine Maleate, Aripiprazole, Olanzapine
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Asenapine maleate, aripiprazole, olanzapine, quetiapine fumarate, clocapramine hydrochloride hydrate, chlorpromazine hydrochloride, chlorpromazine hydrochloride/promethazine hydrochloride/phenobarbital, chlorpromazine phenolphthalinate, spiperone, zotepine, timiperone, haloperidol, paliperidone, pipamperone hydrochloride, fluphenazine decanoate, fluphenazine maleate, brexpiprazole, prochlorperazine maleate, prochlorperazine mesilate, Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. propericiazine, bromperidol, perphenazine, perphenazine hydrochloride, perphenazine fendizoate, perphenazine maleate, perospirone hydrochloride hydrate, mosapramine hydrochloride, risperidone (oral drug), levomepromazine hydrochloride, levomepromazine maleate March 27, 2018 Non-proprietary name Asenapine maleate,
    [Show full text]
  • WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/123576 Al 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: Unit L, Baltimore, Maryland 21209 (US). WEINBER¬ A61K 31/535 (2006.01) GER, Daniel; 3116 Davenport St. NW, Washington, Dis trict of Columbia 20008-2244 (US). (21) International Application Number: PCT/US2016/015832 (74) Agent: KELLY, Bryte; King & Spalding LLP, 1185 Av enue of the Americas, New York, New York 10036 (US). (22) International Filing Date: 29 January 2016 (29.01 .2016) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/109,954 30 January 2015 (30.01.2015) US KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: LIEBER INSTITUTE FOR BRAIN DE¬ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, VELOPMENT [US/US]; 855 North Wolfe Street, Suite PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 300, 3rd Floor, Baltimore, Maryland 21205 (US). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • (KPIC) PPO and Out-Of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier
    Kaiser Permanente Insurance Company (KPIC) PPO and Out-of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier This Drug Formulary was updated: September 1, 2021 NOTE: This drug formulary is updated often and is subject to change. Upon revision, all previous versions of the drug formulary are no longer in effect. This document contains information regarding the drugs that are covered when you participate in the California Nongrandfathered PPO and Out-of- Area Indemnity (OOA) Health Insurance Plans with specialty drug tier offered by Kaiser Permanente Insurance Company (KPIC) and fill your prescription at a MedImpact network pharmacy. Access to the most current version of the Formulary can be obtained by visiting kp.org/kpic-ca-rx-ppo-ngf. For help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit, please call 1-800-788-0710 or 711 (TTY) Monday through Friday, 7a.m. to 7p.m. For help with this Formulary, including the processes for submitting an exception request and requesting prior authorization and step therapy exceptions, please call MedImpact 24 hours a day, 7 days a week, at 1-800-788-2949 or 711 (TTY). For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit: kp.org/kpic-ca-rx-ppo-ngf. For help in your preferred language, please see the Kaiser Permanente Insurance Company Notice of Language Assistance in this document. KPIC PPO NGF Table of Contents Informational Section................................................................................................................................2
    [Show full text]
  • Formulary (List of Covered Drugs)
    3ODQ<HDU 202 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THE FOLLOWING PLAN: $0 Cost Share AI/AN HMO Minimum Coverage HMO Silver 70 HMO Active Choice PPO Silver Opal 25 Gold HMO Silver 70 OFF Exchange HMO Amber 50 HMO Silver Opal 50 Silver HMO Silver 73 HMO Bronze 60 HDHP HMO Platinum 90 HMO Silver 87 HMO Bronze 60 HMO Ruby 10 Platinum HMO Silver 94 HMO Gold 80 HMO Ruby 20 Platinum HMO Jade 15 HMO Ruby 40 Platinum HMO This formulary was last updated on8//20. This formulary is VXEMHFWto change and all previous versions of the formulary no longer apply. For more recent information or other questions, please contact Chinese Community Health Plan Member Services at 1-888-775-7888 or, for TTY users, 1-877-681-8898, seven days a week from 8:00 a.m. to 8:00 p.m., or visit www.cchphealthplan.com/family-member -,-ϭ -,-ϭ"&* !#" + 5 5 ),-$+" %(%'.')/"+#" %&/"+ -%/"$)% "%&/"+ *& )&! %&/"+ 0 $(#" '"+ %&/"+ *& %&/"+ %&/"+ +)(2" &-%(.' %&/"+ +)(2" .1&-%(.' %&/"+ )&! .1&-%(.' !" .1&-%(.' dŚŝƐĨŽƌŵƵůĂƌLJǁĂƐůĂƐƚƵƉĚĂƚĞĚ8ͬϭͬϮϬϮϭ͘dŚŝƐĨŽƌŵƵůĂƌLJŝƐƐƵďũĞĐƚƚŽ ĐŚĂŶŐĞĂŶĚĂůůƉƌĞǀŝŽƵƐǀĞƌƐŝŽŶƐŽĨƚŚĞĨŽƌŵƵůĂƌLJŶŽůŽŶŐĞƌĂƉƉůLJ͘&ŽƌŵŽƌĞ ƌĞĐĞŶƚŝŶĨŽƌŵĂƚŝŽŶŽƌŽƚŚĞƌƋƵĞƐƚŝŽŶƐ͕ƉůĞĂƐĞĐŽŶƚĂĐƚŚŝŶĞƐĞŽŵŵƵŶŝƚLJ ,ĞĂůƚŚWůĂŶDĞŵďĞƌ^ĞƌǀŝĐĞƐĂƚϭͲϴϴϴͲϳϳϱͲϳϴϴϴŽƌ͕ĨŽƌddzƵƐĞƌƐ͕ ϭͲϴϳϳͲϲϴϭͲϴϴϵϴ͕ƐĞǀĞŶĚĂLJƐĂǁĞĞŬĨƌŽŵϴ͗ϬϬĂ͘ŵ͘ƚŽϴ͗ϬϬƉ͘ŵ͕͘ŽƌǀŝƐŝƚ ǁǁǁ͘ĐĐŚƉŚĞĂůƚŚƉůĂŶ͘ĐŽŵͬĨĂŵŝůLJͲŵĞŵďĞƌ !! %+)&,+ &%+&+&)$,#)0),# *+666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I % + &%*6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I
    [Show full text]
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES
    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
    [Show full text]